-
Pharmasset Moving Back Up Again
Wednesday, June 8, 2011 - 2:25pm | 100Pharmasset, Inc. (NASDAQ: VRUS) shares are moving back towards session highs, after a steep sell off following positive news this morning. Shares started the session up nearly 25% on news that the company's hepatitis C drug was essentially effective, as the Princeton, N.J.-based company said it...
-
Pharmasset Gives Up Almost All Of Earlier Gains
Wednesday, June 8, 2011 - 12:37pm | 139Pharmasset, Inc. (NASDAQ: VRUS) shares were soaring at the beginning of the trading session, up nearly 25% after the company announced it would be expanding its hepatitis C drug study to include more patients. Traders, analysts and the rest of Wall Street took this as a sign to mean that the drug...
-
Pharmasset Spiking Higher after Clinical Results This Morning
Wednesday, June 8, 2011 - 10:38am | 136Pharmasset (Nasdaq: VRUS) announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C. The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI-...
-
Top Narrow Based Indexes For June 8
Wednesday, June 8, 2011 - 10:28am | 213By 10:26 am, the Dow Jones Industrial Average was up 3.48 points, or 0.03%, to 12,074.29, while the broader Standard & Poor's 500 index had dropped 2.58 points, or 0.20%. The NASDAQ composite index fell 13.81 points, or 0.51%. Some of the narrow based indexes that are supporting the markets...
-
Benzinga's Volume Movers
Wednesday, June 8, 2011 - 10:18am | 152Ulta Salon, Cosmetics & Fragrance, Inc (NASDAQ: ULTA) shares surged 9.19% to $54.17 at 10:17 am. The volume of ULTA shares traded was 721% higher than normal. ULTA reported upbeat Q1 results and issued stronger-than-expected Q2 earnings forecast. Pharmasset Inc (NASDAQ: VRUS) shares moved up...
-
NASDAQ Stocks Hitting 52-Week Highs
Wednesday, June 8, 2011 - 10:11am | 139Pharmasset Inc (NASDAQ: VRUS) shares rose 23.37% to create a new 52-week high of $133.61. VRUS expanded its study of hepatitis C drug candidate PSI-7977. Hickory Tech Corporation (NASDAQ: HTCO) shares gained 2.15% to create a new 52-week high of $11.39. HTCO's trailing-twelve-month ROE is 33.21...
-
Pharmasset Spiking 25%
Wednesday, June 8, 2011 - 9:52am | 100Pharmasset, Inc. (NASDAQ: VRUS) shares are soaring this morning, gaining more than 25% after the company announced it would be expanding its hepatitis C study, suggesting that the drug works. The drug, known as PSI-7977, is used for treating hepatitis C, and the company said that it is adding new...
-
Morning Market Movers
Wednesday, June 8, 2011 - 9:50am | 123FiberTower Corporation (NASDAQ: FTWR) shares advanced 23.53% to $1.47 at 9:45 am. FTWR shares have dropped 65.20% over the past 52 weeks, while the S&P 500 index has gained 20.99% in the same period.. Pharmasset Inc (NASDAQ: VRUS) shares surged 19.34% to $129.24. VRUS expanded its study of...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Wednesday, June 8, 2011 - 8:15am | 144Cytori Therapeutics Inc (NASDAQ: CYTX) shares advanced 15.32% to $5.87 in the pre-market session. CYTX announced sustained benefits at 18 months in cardiac cell therapy heart attack trial. Ulta Salon, Cosmetics & Fragrance, Inc (NASDAQ: ULTA) shares advanced 13.73% to $56.42 in the pre-market...
-
UPDATE: Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
Wednesday, June 8, 2011 - 7:43am | 122Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C. The rapid and consistent antiviral effects and high barrier to resistance demonstrated with...
-
RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVaxTM and Trastuzumab Breast Cancer at ASCO
Wednesday, June 8, 2011 - 7:41am | 93RXi Pharmaceuticals Corporation (NASDAQ: RXII) presented Phase 2 efficacy results for NeuVax™ in combination with trastuzumab (Herceptin®; Genentech/Roche) at the American Society of Clinical Oncology annual meeting. The poster entitled, “Sequential administration of trastuzumab and a CD8 T cell-...
-
Health Canada Approves Amgen's Xgeva™ for Reducing Risk of Developing Skeletal-Related Events in Patients with Bone Metastases from Solid Tumours
Wednesday, June 8, 2011 - 7:36am | 268Amgen (NASDAQ: AMGN) Canada today announced that Health Canada has approved XGEVA™ (denosumab), a RANK Ligand inhibitor, for reducing the risk of developing skeletal-related events pathological fracture, radiation to bone, spinal cord compression or surgery to bone] in adults with bone metastases...
-
Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
Wednesday, June 8, 2011 - 6:46am | 210Pharmasset (Nasdaq: VRUS) announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C. The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI-...
-
Mad Money Lightning Round OT: Cramer Is Bearish On MNKD (ULTA, MNKD, RFMD, SWKS, OVTI)
Tuesday, June 7, 2011 - 7:28pm | 209On CNBC's Mad Money Lightning Round OT, Jim Cramer advised his viewers to buy Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ: ULTA). Although Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA) spiked 13.38% in the after hours, Cramer sees more upside for this stock. MannKind Corporation (...
-
Immunomedics Announces Antibody-Directed Radiation Therapy Appears to Improve Response to Standard-of-Care for Aggressive Lymphoma
Tuesday, June 7, 2011 - 4:32pm | 101Immunomedics, Inc. (Nasdaq: IMMU) today reported that smaller doses of epratuzumab labeled with yttrium-90 given repeatedly to elderly patients with diffuse large B-cell lymphoma appears to improve their response to the combination of rituximab and CHOP chemotherapy, the standard of care for this...